Scarica l'app Stockscreener
1.35
0.75%
0.01
Dopo l'orario di chiusura:
1.40
0.05
+3.70%
Precedente Chiudi:
$1.34
Aprire:
$1.35
Volume 24 ore:
345.52K
Relative Volume:
0.76
Capitalizzazione di mercato:
$60.16M
Reddito:
$19.94M
Utile/perdita netta:
$-37.37M
Rapporto P/E:
-1.2981
EPS:
-1.04
Flusso di cassa netto:
$-33.38M
1 W Prestazione:
-6.25%
1M Prestazione:
-8.78%
6M Prestazione:
-44.90%
1 anno Prestazione:
-72.56%
Intervallo 1D:
$1.28
$1.42
Intervallo di 1 settimana:
$1.28
$1.48
Portata 52W:
$1.28
$8.1939
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Nome
Werewolf Therapeutics Inc
Settore
Industria
Telefono
617-952-0555
Indirizzo
200 TALCOTT AVENUE, WATERTOWN
Confronta HOWL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.35 | 60.16M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-03 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-08-24 | Iniziato | Wedbush | Outperform |
| 2023-06-06 | Ripresa | Jefferies | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-25 | Iniziato | Evercore ISI | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-25 | Iniziato | Jefferies | Buy |
| 2021-05-25 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Werewolf Therapeutics Inc Borsa (HOWL) Ultime notizie
Harmony Biosciences (NASDAQ:HRMY) vs. Werewolf Therapeutics (NASDAQ:HOWL) Head to Head Review - Defense World
Barclays PLC Increases Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in December - MarketBeat
Jane Street Group LLC Trims Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics' SWOT analysis: stock faces challenges amid pipeline progress - Investing.com
Werewolf Therapeutics (NASDAQ:HOWL) Price Target Lowered to $4.00 at JMP Securities - MarketBeat
JMP Securities Cuts Price Target for Werewolf Therapeutics (NASDAQ:HOWL) to $4.00/Share, Down from $12.00 - HPBL
Werewolf Therapeutics provides business update, highlights 2025 outlook - Yahoo Finance
Werewolf Therapeutics Provides Business Update - citybiz
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook - GlobeNewswire
Werewolf Therapeutics Unveils Ambitious 2025 Pipeline Plans for Cancer Immunotherapy Programs - StockTitan
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Acquired by Geode Capital Management LLC - Defense World
Barclays PLC Buys 30,990 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
State Street Corp Has $1.01 Million Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 23.6% in December - MarketBeat
Werewolf Therapeutics stock hits 52-week low at $1.58 By Investing.com - Investing.com UK
Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Drops By 6.1% - Defense World
Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 6.1% - MarketBeat
Werewolf Therapeutics' SWOT analysis: oncology stock's potential amid clinical trials - Investing.com Australia
HC Wainwright Reaffirms “Buy” Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - The Manila Times
Werewolf Therapeutics stock hits 52-week low at $1.62 - Investing.com India
Werewolf Therapeutics stock hits 52-week low at $1.62 By Investing.com - Investing.com Canada
Werewolf Therapeutics stock holds buy rating amid investor concerns over cytokine therapies By Investing.com - Investing.com Canada
HC Wainwright Reaffirms "Buy" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat
PFM Health Sciences, LP Increases Stake in Werewolf Therapeutics Inc - GuruFocus.com
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Equities Analysts Set Expectations for HOWL FY2024 Earnings - MarketBeat
Werewolf Therapeutics' SWOT analysis: oncology biotech's stock potential amid clinical progress - Investing.com Australia
What is HC Wainwright's Forecast for HOWL Q1 Earnings? - MarketBeat
Werewolf Therapeutics reports promising trial data for cancer drug By Investing.com - Investing.com South Africa
Werewolf Therapeutics Inc (HOWL) Quarterly 10-Q Report - Quartz
Werewolf Therapeutics reports promising trial data for cancer drug - Investing.com
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Presents Preclinical and Clinical - GlobeNewswire
Werewolf's WTX-330 Shows Promise in Phase 1 Trial: Melanoma Patient Responds to Novel IL-12 Therapy | HOWL Stock News - StockTitan
Werewolf Therapeutics Reports Breakthrough Cancer Trial Results Despite $16.7M Loss | HOWL Stock News - StockTitan
Werewolf Therapeutics announces IL-10 Indukine development candidate for inflammatory bowel disease - BioWorld Online
Werewolf Therapeutics expands pipeline with new IBD candidate By Investing.com - Investing.com South Africa
Werewolf Therapeutics expands pipeline with new IBD candidate - Investing.com
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases - The Manila Times
Werewolf Therapeutics Announces Promising New Development - GlobeNewswire
WisdomTree Inc (NYSE: WT): Blank Check On Growth? - Stocks Register
Werewolf To Provide Clinical Update On WTX-330 - RTTNews
Werewolf Therapeutics Inc (NASDAQ: HOWL) Could Pass $12 In One Year Stock Forecast - Stocks Register
Social Security Just Released the 2025 COLA. Here's What It Means for Those Receiving Spousal Benefits. - Yahoo! Voices
Could Buying Apple Stock Today Set You Up for Life? - Yahoo! Voices
Is Summit Therapeutics Inc. (SMMT) the Best QQQ Stock to Buy According to Analysts? - Yahoo Finance
Lyft is working on a ‘service animal opt-in feature’ for passengers - Yahoo! Voices
Werewolf Therapeutics Inc Azioni (HOWL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):